Latest Stories
Uncategorized
Suki Raises $90 Million to Push Its AI Medical Scribe Beyond Note-Taking Into Full Clinical Agents
Suki AI raised a $90 million Series E to expand its ambient scribe beyond note-taking into broader clinical agent tasks, entering a crowded field that includes Abridge, Ambience and Epic's own built-in tool.
Uncategorized
Oracle and AstraZeneca Team Up to Let AI Find Clinical Trial Patients Faster
Oracle Health and AstraZeneca are partnering to use AI for clinical trial patient recruitment, part of a broader industry push to speed up drug trials.
Uncategorized
Roche’s $1.05 Billion Bet on AI Pathology Nears the Finish Line
Roche's deal to acquire AI pathology startup PathAI, announced in May, is working toward a close as the pharmaceutical giant looks to speed up cancer diagnosis using artificial intelligence.
Uncategorized
Tempus AI’s $1.5 Billion Personalis Deal Tests Investor Patience on Genomics Bet
Tempus AI is pushing ahead with a roughly $1.5 billion all-stock acquisition of genomic testing company Personalis, a bet on expanding its precision oncology platform that sent both companies' shares lower when it was announced.
In-Depth
Uncategorized
Pfizer Licenses Chai Discovery’s AI Platform to Speed Up Its Own Drug Pipeline
Pfizer has licensed Chai Discovery's AI protein design platform for its drug pipeline, as the startup diversifies beyond its existing Eli Lilly partnership following a $400 million funding round.
Uncategorized
AI Drug Discovery Licensing Deals Hit $47.1 Billion in Just the First Half of 2026
AI drug discovery licensing deals hit $47.1 billion in the first half of 2026, already surpassing all of 2025, even as no AI-discovered drug has yet won full FDA approval.
Uncategorized
Takeda Signs $600 Million AI Drug Discovery Deal With Insilico Medicine
Takeda signed a $600 million AI drug discovery deal with Insilico Medicine, joining Eli Lilly and AstraZeneca in a wave of major pharma bets on AI-driven drug development in 2026.
Uncategorized
Eli Lilly Expands AI Drug Discovery Bet With $2.75 Billion Insilico Medicine Deal
Eli Lilly signed a deal worth up to $2.75 billion with Insilico Medicine to develop new drugs using AI, one of 2026's largest AI drug discovery partnerships.
Uncategorized
WellSpan Health Expands Hippocratic AI Deal to Platform-Wide Use Across Every Care Setting
WellSpan Health expanded its partnership with Hippocratic AI on July 30, 2026 into a platform-wide, multi-year deal covering inbound, outbound, ambulatory, and inpatient care, moving its Ana voice agent beyond scheduling into clinical navigation.
